Izvleček / Abstract
KRITIKA SISTEMA REFERENČNIH CEN ZDRAVIL
THE DISADVANTAGES OF THE REFERENCE PRICING SYSTEM FOR MEDICINES
Dr. Mejra Festić, docentka
Univerza v Mariboru, Ekonomsko-poslovna fakulteta
Izvleček
UDK: 338:58:614.27
Sistem referenčnih cen je bil uveden v državah, kjer so se cene zdravil oblikovale svobodno. Nadomestil je sistem direktne kontrole reimbursiranja za posamezna zdravila. Sistem referenčnih cen je stroškovno naravnan in neodvisen od sprememb v obsegu porabe zdravil. Sistem referenčnih cen je omogočal, da so se cene originatorjev zniževale, cene generikov pa povečevale. Ker sistem referenčnih cen dopušča, da se cene generikov povečujejo, se profiti inovativnosti prerazdelijo v korist generikov.
Ključne besede: porab zdravil, cene zdravil, reimbursirani znesek, izdatki za raziskave in razvoja zdravil
UDC: 338:58:614.27
The system of reference pricing was introduced in economies where the prices of drugs have been formed freely, and it has replaced the system of direct reimbursement control of specific drugs. The system of reference pricing is directed toward cost control rather than control of quantity consumed. The system of reference pricing has enabled the price of generics to increase, while the price of non-generic drugs has decreased. Because the system of reference pricing allows the price of generics to increase, the profits from innovative products have been redistributed in favor of generics.
Key words: quantity of drugs consumed, prices of drugs, reimbursement amount, covering expenditures of research and development of drugs
JEL: I11